NIH Highlighted Topic: Advancing the Use of 3D Technologies Using Human Auditory, Vestibular and Chemosensory Organoids to Create New Approach Models (NAMs) for Treatments
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is seeking innovative research proposals through the SBIR Program focused on advancing human auditory, vestibular, and chemosensory organoid technologies through the integration of 3D modeling systems, bioprinting, AI-driven in silico platforms, and other New Approach Methodologies (NAMs). NIH is particularly interested in technologies that accelerate development of more accurate, reproducible, and scalable models for studying hearing, balance, taste, smell, and related communication disorders.
Current limitations in model systems continue to slow therapeutic discovery and precision medicine advancement for auditory, vestibular, and chemosensory disorders. NIH is encouraging collaborative, interdisciplinary projects that combine human organoid systems with advanced 3D technologies, tissue engineering, computational biology, and artificial intelligence to create highly functional ex vivo models capable of improving translational research and accelerating clinical deliverables. Companies developing organoid platforms, AI-enabled drug discovery systems, 3D bioprinting technologies, biosimulation tools, tissue engineering platforms, precision medicine applications, or advanced sensory-system disease models may be strong candidates for funding.
NIH is especially interested in projects focused on improving organoid reproducibility, stability, functional cell mimicry, and personalized iPSC-based research approaches. Research exploring sex-specific biology, hormonal influences, and women’s health applications within sensory-system disorders is also encouraged.
Through the NIH SBIR Program, U.S. small businesses may apply for up to $323,090 in Phase I funding and up to $2,153,927 in Phase II funding to support research, development, validation, and commercialization activities. Applications are accepted on January 5th, April 5th, and September 5th annually, with funding typically beginning approximately 9 months after submission.
This highlighted topic is supported primarily by the National Institute on Deafness and Other Communication Disorders (NIDCD) and the Office of Research on Women’s Health (ORWH), both of which may give special consideration to high-impact applications advancing organoid science, sensory-system therapeutics, AI-enabled biomedical modeling, and precision medicine technologies.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of technologies and research platforms focused on auditory, vestibular, and chemosensory organoid systems and advanced New Approach Methodologies (NAMs).
Eligible activities may include:
Development of human auditory, vestibular, and chemosensory organoid platforms
3D bioprinting technologies for tissue engineering and sensory-system modeling
AI and machine learning platforms for organoid analysis, predictive modeling, and therapeutic discovery
In silico simulation systems supporting precision medicine and molecular therapeutic development
iPSC-based personalized medicine research platforms
Development of biolinks, tissue replicates, and advanced ex vivo assessment systems
Technologies improving organoid reproducibility, stability, and functional cellular mimicry
Drug discovery and therapeutic screening platforms utilizing organoid and NAM technologies
Biosensors and imaging technologies supporting organoid characterization and validation
Research into hearing, balance, taste, smell, and sensory-system disorders
Sex-specific and women’s health-focused organoid research investigating hormonal and biological influences across life stages
Computational biology and multi-omic approaches supporting sensory-system disease modeling
Translational studies evaluating therapeutic efficacy and safety using advanced organoid systems
Validation studies, prototype development, translational research, and regulatory preparation activities
Commercialization planning and scale-up activities for organoid, tissue engineering, and AI-enabled biomedical technologies
Funding may also support personnel, laboratory testing, software development, computational infrastructure, prototype fabrication, tissue engineering systems, intellectual property protection, commercialization strategy development, and other research and development activities necessary to advance a commercially viable solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
